INNATE PHARMA SA-SPONS ADR (IPHA) Earnings History & Surprises

NASDAQ:IPHA • US45781K2042

Current stock price

1.45 USD
0 (0%)
Last:

IPHA Earnings overview

Past quarterly earnings results for INNATE PHARMA SA-SPONS ADR (IPHA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release Date
N/A
Period
Q2 / 2026
EPS Estimate
-€0.07
Revenue Estimate
7.817M

Last Reported

Most Recent
Release Date
Apr 1, 2026
Period
Q1 / 2026
EPS Reported
-€0.52
EPS Surprise
-353.80%
Revenue Surprise
25.56%

Beat Rate

Last 8 Quarters
0%
EPS and Revenue beats vs estimates

Quarterly Earnings Historical Results

EPS & Revenue History (in EUR): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q1 2026 -0.52 -0.12 -353.80% -395.05% 2.79M 2.222M 25.56% -42.69%
Q4 2025 -0.12 - - 2.787M 2.172M 28.31% -35.62%
Q3 2025 -0.12 - - 1.98M - -
Q2 2025 -0.24 - - 1.671M 4.909M -65.96% -79.85%
Q1 2025 -0.11 - - 4.868M - -
Q4 2024 - - 4.329M - -73.85%
Q2 2024 - - 8.293M - -76.54%
Q4 2023 - - 16.557M - 99.27%
Q2 2023 - - 35.344M - -14.36%
Q4 2022 - - 8.309M - 118.20%
Q2 2022 0.09 - - 41.271M - 397.00%
Q4 2021 -0.59 - -663.62% 3.808M - -85.53%
Q2 2021 - - 8.304M - -72.17%
Q4 2020 -0.08 - - 26.31M 27.379M -3.90% -
Q3 2020 -0.08 - - 27.379M - -
Q2 2020 - - 29.84M - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

IPHA EPS Q2Q GrowthIPHA EPS Q2Q GrowthEPS Q2Q Growth Q4/21 Q1/26 Q2/26 Q3/26 Q4/26 Q1/27 Q2/27 Q3/27 Q4/27 0 -200 -400 -600

Revenue Historical Q2Q growth and Acceleration

IPHA Revenue Q2Q GrowthIPHA Revenue Q2Q GrowthRevenue Q2Q Growth Q2/21 Q4/21 Q2/22 Q4/22 Q2/23 Q4/23 Q2/24 Q4/24 Q2/25 Q4/25 Q1/26 Q2/26 Q3/26 Q4/26 Q1/27 Q2/27 Q3/27 Q4/27 0 100 200 300

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
N/A
Average EPS beat (4)
N/A
Max EPS beat (4)
N/A
Min EPS beat (4)
N/A

Revenue beat statistics

Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A

Analysis

IPHA Overview IPHA Technical Analysis Report IPHA Fundamental Analysis Report IPHA Forecast & Price Target
→ Find peers who consistently beat earnings by at least 10% in the last 4 quarters

INNATE PHARMA SA-SPONS ADR / IPHA Earnings FAQ

When did INNATE PHARMA SA-SPONS ADR (IPHA) report earnings last quarter?

INNATE PHARMA SA-SPONS ADR (IPHA) last reported earnings on 4/1/2026.

Can you provide information on whether INNATE PHARMA SA-SPONS ADR beat earnings estimates in the last quarter?

INNATE PHARMA SA-SPONS ADR (IPHA) missed EPS estimates and beat revenue estimates in the most recent quarter.